JP2025506389A5 - - Google Patents
Info
- Publication number
- JP2025506389A5 JP2025506389A5 JP2024545951A JP2024545951A JP2025506389A5 JP 2025506389 A5 JP2025506389 A5 JP 2025506389A5 JP 2024545951 A JP2024545951 A JP 2024545951A JP 2024545951 A JP2024545951 A JP 2024545951A JP 2025506389 A5 JP2025506389 A5 JP 2025506389A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tau
- subject
- level
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306060P | 2022-02-02 | 2022-02-02 | |
| US63/306,060 | 2022-02-02 | ||
| US202263269394P | 2022-03-15 | 2022-03-15 | |
| US63/269,394 | 2022-03-15 | ||
| US202263364617P | 2022-05-12 | 2022-05-12 | |
| US63/364,617 | 2022-05-12 | ||
| PCT/US2022/079571 WO2023149970A1 (en) | 2022-02-02 | 2022-11-09 | Methods of treatment using p-tau181 level |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506389A JP2025506389A (ja) | 2025-03-11 |
| JP2025506389A5 true JP2025506389A5 (https=) | 2025-11-18 |
Family
ID=84488881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024545951A Pending JP2025506389A (ja) | 2022-02-02 | 2022-11-09 | ｐ－タウ１８１レベルを使用した治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250377367A1 (https=) |
| EP (1) | EP4473009A1 (https=) |
| JP (1) | JP2025506389A (https=) |
| KR (1) | KR20240142535A (https=) |
| AU (1) | AU2022439338A1 (https=) |
| CA (1) | CA3243435A1 (https=) |
| CL (1) | CL2024002309A1 (https=) |
| IL (1) | IL314581A (https=) |
| MX (1) | MX2024009492A (https=) |
| TW (1) | TW202339794A (https=) |
| WO (1) | WO2023149970A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025260029A1 (en) * | 2024-06-14 | 2025-12-18 | Eisai R&D Management Co., Ltd. | Method for quantifying amyloid beta protofibril |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| WO2016005466A2 (en) | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| RS67249B1 (sr) | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
-
2022
- 2022-11-09 AU AU2022439338A patent/AU2022439338A1/en active Pending
- 2022-11-09 CA CA3243435A patent/CA3243435A1/en active Pending
- 2022-11-09 IL IL314581A patent/IL314581A/en unknown
- 2022-11-09 WO PCT/US2022/079571 patent/WO2023149970A1/en not_active Ceased
- 2022-11-09 US US18/835,235 patent/US20250377367A1/en active Pending
- 2022-11-09 MX MX2024009492A patent/MX2024009492A/es unknown
- 2022-11-09 EP EP22822805.2A patent/EP4473009A1/en active Pending
- 2022-11-09 KR KR1020247029332A patent/KR20240142535A/ko active Pending
- 2022-11-09 TW TW111142860A patent/TW202339794A/zh unknown
- 2022-11-09 JP JP2024545951A patent/JP2025506389A/ja active Pending
-
2024
- 2024-07-31 CL CL2024002309A patent/CL2024002309A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025506389A5 (https=) | ||
| JP2024525559A5 (https=) | ||
| Sturmey et al. | Blood biomarkers in ALS: challenges, applications and novel frontiers | |
| Bachurin et al. | Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention | |
| JP2022553329A (ja) | アルツハイマー病を治療するための抗ベータ－アミロイド抗体 | |
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| McAlary et al. | Emerging developments in targeting proteotoxicity in neurodegenerative diseases | |
| JP2022547513A (ja) | アルツハイマー病及び軽度認知障害のバイオマーカー及び治療 | |
| EP4274611A1 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| TW202317192A (zh) | 用於阿茲海默氏症治療的生物標記物 | |
| KR20240142535A (ko) | P-tau181 수준을 사용한 치료 방법 | |
| JP2020515639A (ja) | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト | |
| Panza et al. | Passive tau-based immunotherapy for tauopathies | |
| KR20250114372A (ko) | 타우(tau) pet 수준을 이용하는 치료 방법 | |
| WO2019195133A1 (en) | Methods of treating subjects with an elevated neurofilament light chain level | |
| JP2024540294A5 (https=) | ||
| KR20240053620A (ko) | 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법 | |
| Abanto et al. | Association between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials | |
| TW202313111A (zh) | 治療阿茲海默症之方法 | |
| Shim et al. | An autopsy-proven case-based review of autoimmune encephalitis | |
| CN117999094A (zh) | 抗Aβ初原纤维抗体的皮下配制品及其使用方法 | |
| RU2024103015A (ru) | Биомаркеры для лечения болезни альцгеймера | |
| RU2024125461A (ru) | Способы лечения с применением уровня P-TAU181 | |
| US20230218604A1 (en) | PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY | |
| Matsumoto et al. | Recurrent spinal cord attacks in a patient with a limited form of neuromyelitis optica |